Key result
Inclisiran is linked to sustained ~59% LDL-C reduction over 27 months in secondary prevention.
Why the study?
Does inclisiran reduce LDL-C in secondary prevention patients with ASCVD?
Cohort
Does inclisiran reduce LDL-C in secondary prevention patients with ASCVD?
Answers are grounded in this paper and cite their sources.
Inclisiran provides sustained long-term LDL-C reduction of approximately 59% over 27 months in a real-world secondary prevention setting with a favorable safety profile.
ASCVD is a global concern as it has become central to significant morbidity and mortality. LDL-C is the most important modifiable risk factor in developing ASCVD. Therefore, lowering LDL-C levels is paramount to tackling ASCVD; the lower the LDL-C, the better. Finding the right combination of medications patients are willing to adhere to is necessary for optimal lipid lowering. Inclisiran is a novel LDL-C lowering LLT that has demonstrated around 50% reduction in LDL-C with a low side effect profile. As long-term data is limited for Inclisiran, this retrospective analysis aims to observe whether Inclisiran's benefits are sustained as monotherapy and in combination with other LLTs. After 27 months, the clinic found sustained drops in LDL-C of 59% with good adherence. Only 4% of patients reported experiencing side effects, with 1 individual needing to discontinue the medication due to these effects. Our data indicates that incorporating Inclisiran into a patient's LDL-C treatment plan can provide long-term LDL-C reduction, thereby helping to decrease cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Deaney et al. (2025) conducted a cohort in ASCVD. Inclisiran was evaluated on LDL-C reduction. Inclisiran treatment in secondary prevention patients resulted in a sustained 59% reduction in LDL-C over 27 months, with only 4% of patients reporting side effects.
Synapse has enriched 10 related papers. Consider them for comparative context: